Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone949-595-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$156.47 million
Profitability
Miscellaneous
Employees528
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Endologix (NASDAQ:ELGX) Frequently Asked Questions
What is Endologix's stock symbol?
Endologix trades on the NASDAQ under the ticker symbol "ELGX."
When did Endologix's stock split? How did Endologix's stock split work?
Endologix shares reverse split before market open on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split.
How were Endologix's earnings last quarter?
Endologix, Inc. (NASDAQ:ELGX) announced its quarterly earnings results on Thursday, August, 8th. The medical instruments supplier reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.43. The medical instruments supplier had revenue of $36.24 million for the quarter, compared to analyst estimates of $36.09 million. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%. View Endologix's Earnings History.
When is Endologix's next earnings date?
What guidance has Endologix issued on next quarter's earnings?
Endologix issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $140 million, compared to the consensus revenue estimate of $142.21 million.
What price target have analysts set for ELGX?
4 brokerages have issued 1 year price targets for Endologix's stock. Their predictions range from $7.00 to $30.00. On average, they anticipate Endologix's share price to reach $14.67 in the next twelve months. This suggests a possible upside of 294.3% from the stock's current price. View Analyst Price Targets for Endologix.
What is the consensus analysts' recommendation for Endologix?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix.
What are Wall Street analysts saying about Endologix stock?
Here are some recent quotes from research analysts about Endologix stock:
- 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (9/12/2019)
- 2. BTIG Research analysts commented, ": We reiterate our Overweight rating and are lowering our 12-month price target to $85/share from $86/share on AERI. Aerie Pharmaceuticals reported earnings and hosted a conference call to discuss financial and corporate updates for 4Q18/2018. The quarter produced strong Rhopressa sales of $14.5 million. Our focus in 2019 will be on a potential Rocklatan approval, company guidance for revenue projections, and the international expansion of Aerie’s glaucoma drugs to further penetrate the market potential." (2/26/2019)
Has Endologix been receiving favorable news coverage?
Press coverage about ELGX stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endologix earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Endologix.
Who are some of Endologix's key competitors?
Some companies that are related to Endologix include Apyx Medical (APYX), Inovio Pharmaceuticals (INO), Accuray (ARAY), Soliton (SOLY), SeaSpine (SPNE), Vapotherm (VAPO), Neuronetics (STIM), Repro-Med Systems (REPR), RenovaCare (RCAR), Cytosorbents (CTSO), iCAD (ICAD), T2 Biosystems (TTOO), BRAINSWAY LTD/S (BWAY), Sensus Healthcare (SRTS) and Liquidia Technologies (LQDA).
What other stocks do shareholders of Endologix own?
Who are Endologix's key executives?
Endologix's management team includes the folowing people:
- Mr. John Onopchenko, CEO & Director (Age 60)
- Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)
- Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)
- Mr. Jeffrey S. Brown, Chief Operations Officer
- Mr. Jeremy B. Hayden, Gen. Counsel (Age 49)
Who are Endologix's major shareholders?
Endologix's stock is owned by many different of retail and institutional investors. Top institutional investors include Stephens Inc. AR (0.70%). Company insiders that own Endologix stock include Christopher G Chavez, Gregory D Waller, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View Institutional Ownership Trends for Endologix.
Which major investors are selling Endologix stock?
ELGX stock was sold by a variety of institutional investors in the last quarter, including Stephens Inc. AR. Company insiders that have sold Endologix company stock in the last year include Gregory D Waller and Thomas Wilder. View Insider Buying and Selling for Endologix.
How do I buy shares of Endologix?
Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Endologix's stock price today?
One share of ELGX stock can currently be purchased for approximately $3.72.
How big of a company is Endologix?
Endologix has a market capitalization of $65.51 million and generates $156.47 million in revenue each year. The medical instruments supplier earns $-79,710,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. Endologix employs 528 workers across the globe.View Additional Information About Endologix.
What is Endologix's official website?
How can I contact Endologix?
Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected]
MarketBeat Community Rating for Endologix (NASDAQ ELGX)
MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
